Online inquiry

IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11913MR)

This product GTTS-WQ11913MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CCR2 gene. The antibody can be applied in Inflammatory conditions research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001123041.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 729230
UniProt ID P41597
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ11913MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4568MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ14833MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-75
GTTS-WQ7375MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ9415MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Iomab-B
GTTS-WQ13165MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04518600
GTTS-WQ7817MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK 716155
GTTS-WQ11506MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ2634MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 592
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW